Top Stories
Top Stories
Market Insider

After-hours buzz: JUNO, TEVA, SAGE & more

Tim Clayton | Corbis | Getty Images

Check out the companies making headlines after the bell Tuesday:

Shares of Juno Therapeutics soared in extended trading after the biopharmaceutical company announced that the FDA removed the clinical hold on a cancer drug trial. The trial, dubbed the "ROCKET" trial, focuses on adult patients with relapsed or refractory B cell acute lymphoblastic leukemia.

One hot biotech

Sage Therapeutics climbed slightly after the drugmaker announced positive results for a phase 2 trial involving a new drug to treat postpartum depression.The company said data on 21 patients showed that the company's drug, SAGE-547, achieved a statistically significant reduction in symptoms at 60 hours, compared with a placebo, on a standard depression scale used in clinical research.

CytRx shares dropped after hours after the company's announcement on Tuesday that its cancer drug trial did not meet expectations. "This analysis did not provide for sufficient follow-up for the nearly two-thirds of patients who entered the Phase 3 study after the hold was resolved and enrollment resumed," CytRx reported.

Smaller company AAR, dipped more than 10 percent following the release of its fourth-quarter and fiscal year end 2016 results. The commercial aviation distributor reported diluted earnings of 32 cents a share on $458.2 million in sales.

Teva Pharmaceuticals edged higher after hours. The company announced that it expects second-quarter revenue of $4.9 billion to $5 billion versus previous guidance of $4.8 to $4.9 billion. It expects while non-GAAP earnings in a range of $1.19 to $1.22 per share, compared with a previous range of $1.16 to $1.20 a share.

CNBC's Dan Mangan and Berkeley Lovelace contributed to this report.